We reveal the impacts GLT-1 and its binding to PS1 have on Aβ levels, the Aβ42/40 ratio, PS1 conformation, and γ-secretase activity, potentially guiding new therapeutic strategies in AD. Here, SLC1A2 is linked to Alzheimer disease.